NephroPlus (Nephrocare Health Services) IPO
ClosedAlready have an account? Apply now
NephroPlus (Nephrocare Health Services) IPO details
Schedule of NephroPlus (Nephrocare Health Services)
| Issue open date | 10 Dec 2025 |
| Issue close date | 12 Dec 2025 |
| UPI mandate deadline | 12 Dec 2025 (5 PM) |
| Allotment finalization | 15 Dec 2025 |
| Refund initiation | 16 Dec 2025 |
| Share credit | 16 Dec 2025 |
| Listing date | 17 Dec 2025 |
| Mandate end date | 27 Dec 2025 |
| Lock-in end date for anchor investors (50%) | 14 Jan 2026 |
| Lock-in end date for anchor investors (remaining) | 15 Mar 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About NephroPlus (Nephrocare Health Services)
Nephrocare Health Services (operating under the NephroPlus brand) is a leading provider of dialysis services in India, offering haemodialysis, home haemodialysis, hemodiafiltration, holiday dialysis, dialysis on call, and dialysis on wheels. Founded in 2009 and headquartered in Hyderabad, it operates a network of 447 clinics across 269 cities in 21 states and 4 Union Territories, serving over 33,000 patients annually. The company also has an international presence in the Philippines, Uzbekistan, Nepal, and the Kingdom of Saudi Arabia.
Financials of NephroPlus (Nephrocare Health Services)
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 871.05 |
| Fresh Issue – Proceeds go to the company | 353.40 |
| Offer for sale – Proceeds go to the existing investors | 517.64 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Repayment/ prepayment, in full or part, of all or certain outstanding borrowings and accrued interest | 136 (38%) |
| Capital expenditure | 129 (37%) |
| General corporate purposes and miscellaneous | 88.3 (25%) |
Strengths
- Asia’s largest dialysis provider by treatment volumes.
- 447 centres ensuring broad national geographic reach.
- Innovative models like holiday and mobile dialysis.
- Strong patient base of over 33,000 annually.
- Experienced management backed by private equity funding.
Risks
- Capital-intensive model requiring continuous funding support.
- Quality control challenges across a large clinic network.
- Dependent on kidney disease prevalence and policy support.
- Increasing competition from hospitals and local players.
- High operating costs may pressure profitability margins.
Allotment Status for Nephrocare Health Services
To check your IPO allotment status:
- Visit the Kfin Technologies IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status.
Subscription Figures for Nephrocare Health Services
As per media reports (Link), the Grey Market Premium (GMP) of Nephrocare Health Services is reported at ₹11.5 over the IPO price. This metric is not reliable, and to track IPO interest, it is better to check subscription numbers published by exchanges, which are considered more reliable indicators.
Subscription numbers as of 05:00 PM on December 12, 2025:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 36.79 | 588.82 | 16.01x |
| NII | 28.86 | 515.71 | 17.87x |
| Retail | 67.35 | 112.92 | 1.68x |
| Total | 133.88 | 1219.51 | 9.11x |